Herpangina Treatment Global Market Report 2024

The herpangina treatment market has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.88 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%.The expansion observed in the historical period can be attributed to factors such as viral outbreaks and prevalence, the growth of the pediatric population, development in healthcare infrastructure, public health awareness programs, and advancements in clinical research and treatment for herpangina.

The herpangina treatment market is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new viral strains, a growing focus on pediatric health, adherence to international health regulations, technological innovations in diagnostics, and improvements in healthcare access. Key trends expected in the forecast period encompass the development of topical therapies for oral lesions, the integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, and global health preparedness initiatives.

The herpangina treatment market is anticipated to witness growth due to the increasing prevalence of herpangina. Herpangina is a viral illness that commonly affects children, causing painful sores or ulcers on the tonsils and the back of the throat, typically attributed to coxsackievirus and enteroviruses. Treatment for herpangina aims to alleviate symptoms such as blisters, high fever, mouth or throat discomfort, drooling, and loss of appetite. According to the National Library of Medicine, in China, the incidence of Coxsackievirus (Cox A16) cases rose to 1.09 cases (1/100,000) in 2021 compared to 2020, and other enterovirus cases increased from 4.46 cases (1/100,000) in 2020 to 4.73 cases (1/100,000) in 2021, indicating a surge in herpangina cases and driving market growth.

The growth of the herpangina treatment market is also expected to be fueled by the increasing pediatric population. This population segment, encompassing individuals from birth to adolescence or maturity, requires specific attention in herpangina treatment, focusing on symptom management, supportive care, and ensuring proper hydration. The Federal Interagency Forum on Child and Family Statistics reported around 72.5 million children in the United States in 2022, with a projected increase to 78.2 million by 2050. This rise in the pediatric population is a significant driver for the growth of the herpangina treatment market.

The growth of the herpangina treatment market is expected to be propelled by a surge in healthcare expenditure. Healthcare expenditure encompasses all costs related to health services, nutrition activities, family planning, and emergency aid designated for health. An increase in healthcare spending can contribute to the expansion of resources and the availability of trained healthcare professionals for herpangina treatment. According to the Centers for Medicare & Medicaid Services, the National Health Expenditure (NHE) increased by 2.7% to $4.3 trillion in 2021, reaching $12,914 per person. Projected annual increases of 5.1 percent and a 19.6 percent share of GDP in 2030 indicate sustained growth in healthcare expenditure, driving the herpangina treatment market.

The development of treatments for herpangina-related diseases, such as aphthous stomatitis, is a notable trend gaining traction in the herpangina treatment market. Major companies in the market are actively working on therapies to alleviate pain in individuals with recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company, partnered with Aurena Laboratories AB to create a unique self-absorbing pain relief patch for individuals suffering from recurrent mouth ulcers and aphthous stomatitis, facilitating pain relief and accelerating the natural healing process.

Key players in the herpangina treatment market are focusing on the development of new treatments, including Acetaminophen pain relief products for adults. These products, containing acetaminophen as the active ingredient, aim to relieve pain and reduce fever. In April 2022, Genexa, a US-based pharmaceutical company, introduced 'Genexa Acetaminophen Extra Strength' and 'Acetaminophen PM caplets' for temporary relief from minor aches, discomfort associated with conditions such as the common cold, headaches, backaches, arthritis pain, toothaches, muscular aches, and premenstrual and menstrual cramps. The launch of such products contributes to the diversification and growth of the herpangina treatment market.

Major companies operating in the herpangina treatment market report are Gilead Sciences Inc., Johnson and Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, Sanofi S.A, Novartis AG, Mitsubishi Tanabe Pharma Corporation, F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Bausch Health Companies Inc., Mylan N.V., GlaxosmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Limited, Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the global herpangina treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herpangina treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of herpangina treatment include topical anesthetics, ibuprofen or acetaminophen, and others. Topical anesthetics are a form of local anesthesia applied to the skin's surface or mucous membrane to temporarily numb the affected region. Herpangina is caused by viruses such as coxsackie virus A, coxsackie virus B, enterovirus 71, and echovirus, leading to various symptoms such as high fever, sore throat, blisters or ulcers in the throat and mouth, difficulty swallowing, loss of appetite, headache, neck pain, and swollen lymph glands. These treatments are utilized by various end-users, including hospitals, home care settings, specialty clinics, and others.

The herpangina treatment market research report provides herpangina treatment market statistics, including herpangina treatment industry global market size, regional shares, competitors with a herpangina treatment market share, detailed herpangina treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpangina treatment industry. This herpangina treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The herpangina treatment market consists of revenues earned by entities by providing medical services such as symptomatic relief, hydration, soft diet, and oral hygiene. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.